Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This study evaluates the efficacy of orally administered PHA-022121 for the acute treatment
of attacks in patients with hereditary angioedema (HAE). Eligible subjects are randomized to
one of three single doses of PHA-022121 and placebo. The study will compare symptom relief
(skin pain, skin swelling, abdominal pain) during HAE attacks and safety of each dose of
PHA-022121 with placebo.